Wendy W T Lam1, Michael A Tse2, Chris N L Ng3, Edward K M Chung3, Richard Fielding4. 1. Centre for Psycho-oncology Research and Training, Division of Behavioral Sciences, School of Public Health, The University of Hong Kong, Hong Kong. Electronic address: wwtlam@hku.hk. 2. Institute of Human Performance, The University of Hong Kong, Hong Kong. 3. Hong Kong Cancer Fund, Hong Kong. 4. Centre for Psycho-oncology Research and Training, Division of Behavioral Sciences, School of Public Health, The University of Hong Kong, Hong Kong.
Abstract
PURPOSE: The Expanded Prostate Cancer Index Composite (EPIC) instrument was designed to assess a range of health-related quality-of-life issues specifically relevant to patients with prostate cancer. This study examined the validity and reliability of Chinese versions of the 26-item EPIC and of the 16-item EPIC for Clinical Practice (EPIC-CP) in Chinese patients with prostate cancer. MATERIALS AND METHODS: A Chinese version of the 26-item EPIC and the 16-item EPIC-CP were self-completed by 252 Chinese patients with prostate cancer who were recruited from three community-based cancer service centers. Confirmatory factors analysis assessed the factor structures of the EPIC and the EPIC-CP. Internal consistency and construct and clinical validities of the factor structures were assessed. RESULTS: Confirmatory factor analysis revealed that the original factor structure of both EPIC-26 and EPIC-CP showed good fit to this sample. A correlated model was superior to a hierarchical model in both EPIC-26 and EPIC-CP supporting the utility of the domain scores over the total scores. Cronbach α ranged from 0.55 to 0.91 for EPIC-26 and 0.44 to 0.67 for EPIC-CP. Construct validity was supported by correlations between EPIC-26/EPIC-CP and psychological distress measures. Clinical validity was supported by differentiation between patients with and without prostatectomy. CONCLUSIONS: These Chinese versions of the five-factor EPIC-26 and the EPIC-CP are valid and practical measures for assessing a range of health-related quality-of-life issues related to the diagnosis and treatment of prostate cancer, highlighting their utility in assessing health-related quality of life for patients diagnosed with prostate cancer.
PURPOSE: The Expanded Prostate Cancer Index Composite (EPIC) instrument was designed to assess a range of health-related quality-of-life issues specifically relevant to patients with prostate cancer. This study examined the validity and reliability of Chinese versions of the 26-item EPIC and of the 16-item EPIC for Clinical Practice (EPIC-CP) in Chinese patients with prostate cancer. MATERIALS AND METHODS: A Chinese version of the 26-item EPIC and the 16-item EPIC-CP were self-completed by 252 Chinese patients with prostate cancer who were recruited from three community-based cancer service centers. Confirmatory factors analysis assessed the factor structures of the EPIC and the EPIC-CP. Internal consistency and construct and clinical validities of the factor structures were assessed. RESULTS: Confirmatory factor analysis revealed that the original factor structure of both EPIC-26 and EPIC-CP showed good fit to this sample. A correlated model was superior to a hierarchical model in both EPIC-26 and EPIC-CP supporting the utility of the domain scores over the total scores. Cronbach α ranged from 0.55 to 0.91 for EPIC-26 and 0.44 to 0.67 for EPIC-CP. Construct validity was supported by correlations between EPIC-26/EPIC-CP and psychological distress measures. Clinical validity was supported by differentiation between patients with and without prostatectomy. CONCLUSIONS: These Chinese versions of the five-factor EPIC-26 and the EPIC-CP are valid and practical measures for assessing a range of health-related quality-of-life issues related to the diagnosis and treatment of prostate cancer, highlighting their utility in assessing health-related quality of life for patients diagnosed with prostate cancer.
Authors: Mohannad A Awad; Luke Hallgarth; Ghassan A Barayan; Mohammed Shahait; Ramiz Abu-Hijlih; Ala'a Farkouh; Raed A Azhar; Musab M Alghamdi; Ahmad Bugis; Said Yaiesh; Saad Aldousari; Alaeddin Barham; Mohamed Saed; Ayman Moussa; Waleed Hassen; Shelly Naud; Mark K Plante; Richard Grunert Journal: Arab J Urol Date: 2021-11-28
Authors: Graham R Hale; Mohammed Shahait; David I Lee; Daniel J Lee; Ryan W Dobbs Journal: Patient Prefer Adherence Date: 2021-06-23 Impact factor: 2.711